DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01971242

EXENATIDE-PD

CompletedPhase 2

Trial of Exenatide for Parkinson's Disease

A Randomised, Double Blind, Placebo Controlled, Single Centre, 60 Week Trial of Exenatide Once Weekly for the Treatment of Moderate Severity Parkinson's Disease

Asset

Exenatide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

60

actual

Study population

Parkinson's disease

Key I/E criterion

—

Primary endpoint

•Efficacy

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01971242
Org study ID2013-003363-64

Timeline

Milestones

Study first posted2013-10-29estimated
Last update posted2016-11-17estimated
Study start2014-06 (month precision)
Primary completion2016-05actual (month precision)
Study completion2016-08actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Parkinson's disease

Eligibility

Who can enroll

Minimum age25 Years
Maximum age75 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Diagnosis of Parkinson's disease.
•Males or Females.
•Hoehn and Yahr stage ≤ 2.5 in the On medication state.
•Between 25 and 75 years of age.
•On dopaminergic treatment with wearing off phenomena.
•Ability to self-administer, or to arrange carer administration of trial drug.
•Documented informed consent to participate.

Exclusion criteria

•Diagnosis or suspicion of other cause for parkinsonism.
•Body mass index <18.5.
•Known abnormality on CT or MRI brain imaging considered likely to compromise compliance with trial protocol/DaTSCAN acquisition.
•Concurrent dementia defined by a score lower than 120 on the Mattis Dementia Rating Scale.
•Concurrent severe depression defined by a score >16 on the MADRS.
•Prior intra-cerebral surgical intervention for Parkinson's disease.
•Already actively participating in a trial of a device, drug or surgical treatment for Parkinson's disease.
•Severe gastrointestinal disease (e.g. gastroparesis).
•Previous exposure to Exenatide.
•Severely impaired renal function with creatinine clearance <30ml/min.
•History of pancreatitis.
•Hyperlipidaemia.
•History or suspicion of thyroid cancer
•Known or suspected intolerance of DaTSCAN or Potassium Iodide administration.
•Females that are pregnant or breast feeding.
•Participants who lack the capacity to give informed consent
•Any medical or psychiatric condition which in the investigator's opinion compromises the potential participant's ability to participate.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
2
Safety / tolerability / PK
1

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Safety and tolerability

Time frame:60 weeks

descriptive

Other clinical outcomes

2 endpoints
Primary/protocol endpoint

Efficacy

Time frame:60 weeks

change from baseline, improvement

Other/protocol endpoint/low confidence

Exploratory outcomes

Time frame:Compare differences at 48 and 60 weeks

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.